Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
Status: RecruitingPhase: Phase 1Diagnosis: MelanomaNCT ID: NCT02141542
(View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 13-613
This is an open label, phase I trial, testing the combination of Tremelimumab and MEDI3617 in patients with metastatic melanoma.
Conducting Institutions: Dana-Farber Cancer Institute, Brigham and Women's Hospital, Beth-Israel Deaconess Medical Center
Overall PI: Patrick Ott, MD,
Dana Farber Cancer Institute
Site-responsible Investigators: David McDermott, MD,
Beth Israel Deaconess Medical Center
Contacts: Dana-Farber Cancer Institute:
email@example.comBeth-Israel Deaconess Medical Center:
Cancer Trials Call Center, 617-667-3060